# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional b...
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Neutral and maintains $10 price target.
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and lowers the price target from $17 to $16.
Wells Fargo analyst Derek Archila maintains Zymeworks (NASDAQ:ZYME) with a Overweight and lowers the price target from $14 t...
Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.29) by ...
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional bi...